CD274 and neoplasm: PD-L1 positivity, high TMB, MSI-high, and dMMR are associated with improved treatment responses to CPIs in solid tumors [12,13,14], with pembrolizumab approved for tumor-agnostic indications of TMB ≥ 10 m/MB and MSI-high/dMMR.